LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced a strategic transformation from a clinical-stage pharmaceutical company to an AI energy infrastructure equipment and services platform. The company cited growing power demands from AI and hyperscale data centers as the driver for the business pivot.

Stuart D. Porter, founder of Denham Capital Management LP, joined LIXTE's board of directors effective June 1, 2026. Porter has overseen more than $12 billion of invested and committed capital across energy sectors since founding Denham Capital in 2004.

The transformation follows projections from the North American Electric Reliability Corporation that summer peak demand will increase by 224 gigawatts over the next decade. The organization issued a Level 3 Alert in April 2026 directing grid operators to address reliability risks from large-scale computational loads.

LIXTE's new strategy focuses on power equipment and service solutions for hyperscale AI and data center campuses, equipment for distributed power systems supporting enterprise AI deployments, and strategic acquisitions targeting advanced generation technologies.

"The power problem is the AI problem," said Geordan Pursglove, chief executive officer of LIXTE. "Compute capacity is being built faster than the grid can support it."

The company plans to maintain its NASDAQ listing under the ticker symbol "LIXT" during the transformation process. LIXTE stated it will seek a strategic acquisition partner for its clinical stage pharmaceutical and medical technology operations focused on cancer treatments.

Denham Capital's infrastructure group is developing approximately 10 gigawatts of AI data center-oriented power generation assets in the United States and Europe, according to the company's statement.